UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 775

Sortiert nach

12-O-Tetradecanoylphorbol-13-Acetate Not Only Modulates Proliferation Rates, But Also Alters Antigen Expression and LAK-Cell Susceptibility of Normal Human Melanocytes In Vitro

Journal of investigative dermatology, 1993-05, Vol.100 (5), p.653-659

1993

Link zum Volltext

Verfügbarkeit prüfen

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

European journal of nuclear medicine and molecular imaging, 2018-01, Vol.45 (1), p.95-101

2018

Link zum Volltext

Verfügbarkeit prüfen

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

European journal of nuclear medicine and molecular imaging, 2018, Vol.45 (1), p.95-101

2018

Link zum Volltext

Verfügbarkeit prüfen

30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

Journal der Deutschen Dermatologischen Gesellschaft, 2021-11, Vol.19 (11), p.1682-1697

2021

Link zum Volltext

Verfügbarkeit prüfen

30 years German Dermatologic Cooperative Oncology Group (DeCOG)

Journal der Deutschen Dermatologischen Gesellschaft, 2021-11, Vol.19 (11), p.1682-1697

2021

Link zum Volltext

Verfügbarkeit prüfen

433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A263-A264

2020

Link zum Volltext

Verfügbarkeit prüfen

443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011

European journal of cancer (1990), 2015-05, Vol.51 (7), p.861-868

2015

Link zum Volltext

Verfügbarkeit prüfen

4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17-19, 1992

Pigment cell research, 1992-10, Vol.5 (4), p.168-168

Garbe, Claus

1992

Link zum Volltext

Verfügbarkeit prüfen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Link zum Volltext

Verfügbarkeit prüfen

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5225-5235

2021

Link zum Volltext

Verfügbarkeit prüfen

6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells

Cellular physiology and biochemistry, 2018-11, Vol.51 (2), p.543-556

2018

Link zum Volltext

Verfügbarkeit prüfen

6 Pitfalls in retrospective analysis of data from adjuvant trials

Melanoma research, 1997-04, Vol.7 (2), p.157

Garbe, Claus

1997

Link zum Volltext

Verfügbarkeit prüfen

Absence of merkel cell polyoma virus in cutaneous melanoma: Letter to the Editor

Experimental dermatology, 2011-01, Vol.20 (1), p.78-79

2011

Link zum Volltext

Verfügbarkeit prüfen

Absence of merkel cell polyoma virus in cutaneous melanoma

Experimental dermatology, 2011-01, Vol.20 (1), p.78-79

2011

Link zum Volltext

Verfügbarkeit prüfen

Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy

Australasian journal of dermatology, 2020-08, Vol.61 (3), p.e310-e318

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1233: Immunological biomarkers predicting survival in late-stage melanoma patients

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1233-1233

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2547-2547

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3034: 18F-FDG-positron emission tomography (PET)/CT enables the identification of checkpoint inhibitor immunotherapy (CIT) responders by determination of CIT-induced metabolic changes in secondary lymphatic organs

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3034-3034

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5506-5506

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5582: NY-ESO-1-specific T-cells in melanoma patients with good clinical outcome after vaccination using mRNA as the immunogen

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.5582-5582

2010

Link zum Volltext

Verfügbarkeit prüfen

Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.6403-6403

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract PR-1: AGENDA: Results of a randomized, double-blind phase III trial of dacarbazine with or without Bcl-2 targeted therapy (oblimersen) in a biomarker-defined patient population with advanced melanoma

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.PR-1-PR-1

2009

Link zum Volltext

Verfügbarkeit prüfen

Acceptance and reliability of an electronic psychooncological screening of patients with breast cancer: a randomized controlled study

Psychotherapie, Psychosomatik, medizinische Psychologie, 2013-09, Vol.63 (9-10), p.374

2013

Link zum Volltext

Verfügbarkeit prüfen

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e18609-e18609

2018

Link zum Volltext

Verfügbarkeit prüfen

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Cancer Immunology, Immunotherapy, 2018-12, Vol.67 (12), p.1845-1851

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 775

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(717)
Mit Volltextzugriff
(732)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(724)
Japanisch
(70)
Deutsch
(69)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

12-O-Tetradecanoylphorbol-13-Acetate Not Only Modulates Proliferation Rates, But Also Alters Antigen Expression and LAK-Cell Susceptibility of Normal Human Melanocytes In Vitro

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start

30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO)

30 years German Dermatologic Cooperative Oncology Group (DeCOG)

433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011

4th ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR PIGMENT CELL RESEARCH Berlin, Germany, September 17-19, 1992

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells

6 Pitfalls in retrospective analysis of data from adjuvant trials

Absence of merkel cell polyoma virus in cutaneous melanoma: Letter to the Editor

Absence of merkel cell polyoma virus in cutaneous melanoma

Absolute and relative differential blood count predicts survival of AJCC stage I‐II melanoma patients scheduled for sentinel lymph node biopsy

Abstract 1233: Immunological biomarkers predicting survival in late-stage melanoma patients

Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma

Abstract 3034: 18F-FDG-positron emission tomography (PET)/CT enables the identification of checkpoint inhibitor immunotherapy (CIT) responders by determination of CIT-induced metabolic changes in secondary lymphatic organs

Abstract 5506: Trabedersen (AP 12009) for the treatment of patients with advanced tumors: A phase I/II study

Abstract 5582: NY-ESO-1-specific T-cells in melanoma patients with good clinical outcome after vaccination using mRNA as the immunogen

Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study

Abstract PR-1: AGENDA: Results of a randomized, double-blind phase III trial of dacarbazine with or without Bcl-2 targeted therapy (oblimersen) in a biomarker-defined patient population with advanced melanoma

Acceptance and reliability of an electronic psychooncological screening of patients with breast cancer: a randomized controlled study

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy

Aktive Filter

Suchergebnisse filtern